Aspirin And Extended - Release Dipyridamole Capsules, 25 Mg / 200 Mg Capsule
Product Images NDC 0904-7056

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Aspirin And Extended - Release Dipyridamole Capsules, 25 Mg / 200 Mg (NDC 0904-7056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (0cc3d781 846e 4f18 848e 2b4c2571e6a4 00)

Carton Label (0cc3d781 846e 4f18 848e 2b4c2571e6a4 00)
This is a description of a medication produced by Major Pharmaceuticals. The medication is a unit dose of aspirin combined with extended-release dipyridamole capsules. Each capsule contains 25 mg of aspirin and 200 mg of dipyridamole. The medication is only available by prescription and comes in a package of 20 capsules. The label includes storage information, precautions, and warnings, including advice to store the medication at room temperature and protect it from excessive moisture. There is also a caution to keep the medication out of reach of children.*
FDA Label Image

Dipyridamole (Aspirin And Extended Release Dypyridamole Capsules 1)

Dipyridamole (Aspirin And Extended Release Dypyridamole Capsules 1)
Cp4HyNgO4 is a chemical compound with a molecular weight of 504.63. However, no further information is available.*
FDA Label Image

Aspirin (Aspirin And Extended Release Dypyridamole Capsules 2)

FDA Label Image

Aspirin (Aspirin And Extended Release Dypyridamole Capsules 3)

Aspirin (Aspirin And Extended Release Dypyridamole Capsules 3)
This is a graph showing the cumulative stroke rate (%) for different treatment groups (ridamole, placebo, aspirin, and extended-release dipyridamole) over 24 months of follow-up. The cumulative stroke rate is plotted on the y-axis with values ranging from 0-20%. The x-axis represents the months of follow-up. There is no additional useful information in the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.